补C1QB和结直肠癌之间的因果关系:一种药物向的门德尔式随机化研究
Mingwen Jiao1, Yuying Cui2, Xiaodong Qiu3
1Department of General Surgery, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong, China.
Frontiers in genetics
|August 7, 2024
概括
这项研究发现C1QB是结直肠癌 (CRC) 的风险因素,这表明它可能是潜在的药物标. 准C1QB可能会改善CRC药物开发的成功,并降低成本.
科学领域:
- 遗传学和分子生物学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 结肠直肠癌 (CRC) 受遗传和生活方式因素的影响.
- 补充成分1q B链 (C1QB) 已与各种癌症有关,但其在CRC中的具体作用尚不清楚.
- 调查C1QB和CRC之间的因果关系对于理解CRC病原体和开发向疗法至关重要.
研究的目的:
- 使用孟德尔随机化 (MR) 分析,探索C1QB和结直肠癌 (CRC) 之间的双向因果关系.
- 评估C1QB作为CRC治疗的潜在药物标.
- 确定潜在的治疗策略和药物,针对CRC中的C1QB.
主要方法:
- 利用了针对C1QB和CRC的全基因组关联研究 (GWAS).
- 采用了五种门德尔随机化 (MR) 策略来评估因果关系.
- 进行了灵敏度分析,包括对异质性,水平变性和留出一个效应的测试.
- 进行了局部化分析,蛋白与蛋白相互作用 (PPI) 网络分析和药物/疾病预测.
主要成果:
- 前期MR分析表明,C1QB是CRC的危险因素 (OR = 1.104,p = 0.033).
- 在反向MR分析 (CRC到C1QB) 中没有发现显著的因果关系.
- 确定了C1QB与其他10个基因之间的相互作用,预测了21种潜在的药物,并发现了与29种疾病的关联.
结论:
- C1QB在结直肠癌 (CRC) 中起着致癌作用,建立了因果关系.
- 在CRC药物开发中,C1QB是一个有前途的治疗标.
- 针对C1QB可能会提高CRC药物在临床试验中的成功率,并降低开发成本.
更多相关视频
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
11.8K
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
239
相关概念视频
00:49Complementation Tests
4.9K
A complementation test is a simple cross to identify whether the two mutations are located on the same gene or different genes. It was first performed by Edward Lewis in the 1940s while working on fruit flies. He developed the test to identify the location and arrangement of different mutations on chromosomes.
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
4.9K
01:25Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K